Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 6
2010 8
2011 11
2012 28
2013 26
2014 29
2015 23
2016 24
2017 24
2018 13
2019 17
2020 28
2021 24
2022 17
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: yoon dh. J Clin Oncol. 2024 Mar 28:JCO2302329. doi: 10.1200/JCO.23.02329. Online ahead of print. J Clin Oncol. 2024. PMID: 38547425
Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202).
Cho H, Kim K, Yoon SE, Jung SH, Lee JJ, Moon JH, Cho HJ, Lee HS, Kang KW, Kim SY, Eom HS, Mun YC, Park YH, Yoon SS, Do YR, Lee WS, Min CK, Yoon DH. Cho H, et al. Among authors: yoon dh. Hemasphere. 2024 Jan 26;8(1):e33. doi: 10.1002/hem3.33. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434530 Free PMC article. No abstract available.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: yoon dh. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M. Zhang Y, et al. Among authors: yoon dh. Mol Cancer. 2023 Dec 9;22(1):200. doi: 10.1186/s12943-023-01886-9. Mol Cancer. 2023. PMID: 38066564 Free PMC article.
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
Kim SJ, Jo JC, Yoon DH, Yang DH, Yoon SE, Lee GW, Kong JH, Park Y, Kang KW, Lee HS, Oh SY, Shin HJ, Lee WS, Choi YS, Jeong SH, Kim MK, Kang HJ, Yi JH, Lim SN, Yhim HY, Do YR, Yun HJ, Eom HS, Lee MH, Suh C, Kim WS. Kim SJ, et al. Among authors: yoon dh. Front Oncol. 2023 Aug 22;13:1230629. doi: 10.3389/fonc.2023.1230629. eCollection 2023. Front Oncol. 2023. PMID: 37675232 Free PMC article.
254 results